Skip to main content

RDD (CTN-0100)

The RDD Study is a two-phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD): 

  • The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). (Update: The Retention Phase is now closed to accrual at our site). 
  • The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue or taper the use of Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue MOUD. 

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue or taper MOUD.
  3. To develop models to predict who is able to discontinue or taper MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

Study Team


If you or someone you know would like to learn more about possibly joining our study, please provide your contact information below or you can contact us at 385-256-3882 and/or